Video Series: Current Topics in the Treatment of Advanced PCa

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Latest Prostate Cancer Features

Simpler Prostate Cancer Grading System Proposed

Simpler Prostate Cancer Grading System Proposed

Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.

Latest Prostate Cancer News

Prostate Cancer Diagnosis Ups Risk of Non-Cancer Hospitalizations

Prostate Cancer Diagnosis Ups Risk of Non-Cancer Hospitalizations

Risk of being admitted for non-cancer conditions is 38% higher in the year after a PCa diagnosis compared with a year before.

Steps for Reducing CVD Risks in Prostate Cancer Patients

Steps for Reducing CVD Risks in Prostate Cancer Patients

The advice is useful as clinicians wait for formal guidelines.

Study Supports Hemiablation HIFU for Prostate Cancer

Study Supports Hemiablation HIFU for Prostate Cancer

Ablating only the prostate lobe with the tumor resulted in satisfactory mid-term functional outcomes, researchers reported.

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.

PCa Expectant Management Linked With Veterans' Age, Tumor Risk

PCa Expectant Management Linked With Veterans' Age, Tumor Risk

Patient age and tumor risk may be more strongly associated with use of expectant management for veterans with low-risk prostate cancer.

Targeted Prophylaxis Before Prostate Biopsy Cuts Sepsis Risk

Targeted Prophylaxis Before Prostate Biopsy Cuts Sepsis Risk

Antibiotics selected based on results of pre-biopsy rectal swab cultures.

Chemoimmunotherapy May Be Effective for mCRPC

Chemoimmunotherapy May Be Effective for mCRPC

Combination angiogenesis inhibition can be safely administered with supportive measures in metastatic castration-resistant prostate cancer (mCRPC).

Modest Survival Benefit with EBRT + Brachytherapy in Intermediate PCa

Modest Survival Benefit with EBRT + Brachytherapy in Intermediate PCa

Combined radiotherapy remains controversial due to the increased potential for toxicities.

Fatal Prostate Cancer Linked to Balding

Fatal Prostate Cancer Linked to Balding

Any baldness is associated with a 56% higher risk of dying from the malignancy.

Many Seniors Have Non-Recommended PSA Screening

Many Seniors Have Non-Recommended PSA Screening

Rate of unnecessary screening was 15.7% in men 65 years and older.

PCa Surgery Patients Largely Unaware of Sexual Complications

PCa Surgery Patients Largely Unaware of Sexual Complications

Many men are unaware of erectile function recovery time and problems with ejaculation.

Superficial Sling Implantation Eases Post-RP Incontinence

Superficial Sling Implantation Eases Post-RP Incontinence

Modified technique improved stress urinary incontinence in nearly three-quarters of patients.

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.

Enzalutamide More Effective than Bicalutamide in mCRPC Patients

Enzalutamide More Effective than Bicalutamide in mCRPC Patients

Enzalutamide reduced the risk of disease progression by 56% in mCRPC patients.

DNA Damage, Repair Profiling a Biomarker of PCa Progression

DNA Damage, Repair Profiling a Biomarker of PCa Progression

A newly developed profiling method may be helpful in the management of patients with high-risk prostate cancer.

Prostate Cancer Videos

Sign up for free e-Newsletters